Drug firm ups doses of swine flu vaccine
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GlaxoSmithKline said its has been in discussion with over 50 countries over its swine flu vaccine as it announced contracts for 195 million doses worldwide were in place.
The drug firm said it expected further "significant orders" of the H1N1 vaccine and said that shipments of the medicine were expected in the second half of this year and early 2010.
Glaxo said it also plans to triple the availability of its swine flu treatment Relenza to 190 million doses per year by the end of 2009.
Glaxo said it had worked closely with the World Health Organisation (WHO) throughout the outbreak, starting production of the swine flu vaccine after the virus was declared a pandemic last month.
So far the WHO estimates more than 700 people have died from H1N1 worldwide and 31 deaths have now been recorded in the UK.
Chief executive Andrew Witty said: "Last month, we started production of an H1N1 adjuvanted vaccine and we are on track to meet the orders placed by many governments and the WHO for the vaccine and our novel adjuvant.
"To date we have contracts in place to supply 195 million doses of the vaccine."
He said it also had a "variety of agreements" with the US Government to supply pandemic products worth £152.3 million.
"Discussions with over 50 governments are ongoing, with many at advanced stages, and I therefore expect further significant orders", he said.
"In these last three months, governments have rapidly strengthened their pandemic stockpile and prevention strategies, and whilst we are currently seeing a heightened period of demand, it is likely that we will see a sustained level of orders for pandemic products over the next few years."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments